Industry News

Accelerate Diagnostics, Inc. announced today it will report second-quarter 2016 financial results on Monday, August 8 th.. President and Chief Executive Officer, Lawrence Mehren, joined by Steve Reichling, Chief Financial Officer, will host a conference call to review the results at 4:15 p.m. ET. The quarterly financial results will be accessible through the company’ s website at http://ir.axdx.com or through the Securities and Exchange Commission..."/>
Accelerate Diagnostics to Report Second-Quarter 2016 Results on August 8
Cigna Corp. by Anthem Inc. could be dead following a decision announced Thursday by the U.S. Department of Justice challenging the deal in federal court, two industry analysts said. But a separate $37 billion acquisition sought by Aetna Inc. of Humana Inc. could still go through, although Hartford-based Aetna may be forced to give up more of its business to win federal approval."/>
What's Next After Feds Move To Block Insurance Mergers? [The Hartford Courant]
Heat Biologics, Inc., an immuno-oncology company developing novel therapies that activate a patient’ s immune system against cancer, announced that the company has suspended the proposed public offering of shares of its common stock previously announced on July 21, 2016. Heat’ s leadership team decided to suspend the proposed public offering to explore alternative options presented to the company.. As previously reported, Heat had cash, cash..."/>
Heat Biologics Announces Suspension of Proposed Public Offering of Common Stock
Gilead Sciences, Inc. today announced that the Committee for Medicinal Products for Human Use, the scientific committee of the European Medicines Agency, has adopted a positive opinion on the company’ s Type II variation application for once-daily Truvada ® in combination with safer sex..."/>
European CHMP Adopts Positive Opinion on Gilead’s Type II Variation Application for Truvada® for Reducing the Risk of Sexually Acquired HIV
Cytori Therapeutics, Inc. will provide a live webcast of its second quarter financial results and business update on Thursday, August 4, 2016 at 5:30 PM Eastern Time. The dial-in information is as follows:. Dial-In Number: +1.877. 402.3914 Conference ID: 54687177."/>
Cytori to Webcast Second Quarter Financial Results on August 4
Inotek Pharmaceuticals Corporation, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases, today announced that the United States Patent and Trademark Office issued a composition of matter patent for the combination of the Company’ s lead product..."/>
Inotek Pharmaceuticals Expands Intellectual Property Portfolio with Combination Patent
Hansa Medical AB on Thursday reported consolidated net result of a negative SEK30.7m, or SEK0.95 per share, for the second quarter of 2016, from April 2016 to June 2016.. This was a decline over a negative result of SEK22.5m, or SEK0.70 per share, in Q2 of 2015.. Net revenues for the quarter were SEK0.5m, flat as compared with Q2 2015.."/>
Hansa Medical widens loss in Q2 2016
DexCom, Inc., the leader in continuous glucose monitoring for patients with diabetes, announced today that the Clinical Chemistry and Clinical Toxicology Devices Panel of the U.S. Food and Drug Administration voted in favor of the proposed non-adjunctive indication for the DexCom G5 Mobile CGM system. This indication would designate the G5 Mobile CGM system as a replacement to fingerstick glucose testing for diabetes treatment decisions."/>
FDA Advisory Committee Votes in Favor of Non-Adjunctive Label for DexCom G5 Mobile CGM System
Ensign Group, Inc. announced today that Ensign and its operating subsidiaries increased their credit facility by $200 million to an aggregate of $450 million. The borrowings are supported by a lending consortium arranged by SunTrust Robinson Humphrey, Inc. and Wells Fargo Securities, LLC.. The new facility matures on February 5, 2021 and includes a $300 million revolving line of credit and a new $150 million term loan component, which will be..."/>
The Ensign Group Announces New $450 Million Credit Facility
Starpharma Holdings Ltd announced on Thursday that it has signed an exclusive license and supply agreement with Shenyang Sky and Land Latex Co Ltd for the manufacture and sale of VivaGel condoms to the Government segment of the Chinese condom market. The company said this agreement follows the signing of the MOU with Sky and Land in December 2015.. Sky and Land is a diversified Chinese company that owns and operates a number of condom manufacturing plants in China."/>
Starpharma enters into license agreement for manufacture and sale of VivaGel condom in China
Merck KgaA bought Sigma-Aldrich in November and combined it with EMD Millipore, the research chemicals and supplies business that Batra runs from Billerica, Mass."/>
Sigma's new boss is committed to St. Louis 'epicenter' [St. Louis Post-Dispatch]
Valeant Pharmaceuticals International, Inc. today announced it has received a Complete Response Letter from the U.S."/>
Valeant Pharmaceuticals Receives Complete Response Letter From The FDA
Valeant Pharmaceuticals International, Inc. today announced it has received a Complete Response Letter from the U.S."/>
Valeant Pharmaceuticals Receives Complete Response Letter From The FDA
Amgen and UCB today announced the submission of a Biologics License Application to the U.S. Food and Drug Administration for romosozumab, an investigational monoclonal antibody for the treatment of osteoporosis in postmenopausal women at increased risk of fracture. Romosozumab works by binding and inhibiting sclerostin, a protein naturally occurring in the bone, thereby increasing bone formation and decreasing..."/>
Amgen And UCB Submit Biologics License Application For Romosozumab To The FDA
State Bank of India said that it has signed a memorandum of understanding with Brookfield Asset Management to purchase distressed assets. Brookfield will commit a little more than a billion dollars to the fund and SBI will contribute up to 5% of the total investments by the fund."/>
Funds chase stressed assets down the rabbit hole [Mint, New Delhi]
Syngene International Ltd, the contract research services arm of biopharmaceutical firm Biocon Ltd, on Thursday reported a 28% increase in net profit for the quarter ended 30 June. It said the performance was led by sustained momentum across key verticals including dedicated centres, discovery services as well as development and manufacturing services. Profit rose to Rs.59.8 crore in the fiscal first quarter, from Rs.46.6 crore in the year-ago period."/>
Syngene Q1 profit rises 28% to Rs59.8 crore [Mint, New Delhi]
Corporate myopia crimps CSR scope [Mint, New Delhi]
Biocon Ltd on Thursday said net profit rose 35% in the quarter ended 30 June led by the company's biosimilars and small molecules businesses, besides higher sales at its contract research arm Syngene International Ltd.. The Bengaluru-based company posted a net profit of Rs.166.6 crore in the first quarter, against Rs.123.9 crore a year ago. Revenue rose 21% to Rs.982.4 crore from Rs.813.9 crore in the year-ago period."/>
Biocon Q1 net rises 35% to Rs167 crore [Mint, New Delhi]

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Most Popular Sectors in the News
Sectors Articles in the last 7 days
Financials648 Articles
Consumer Discretionary593 Articles
Information Technology569 Articles
Industrials438 Articles
Health Care379 Articles

Sponsored Financial Commentaries

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact , please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.